Package Leaflet: Information for the User
Carvedilol Sandoz 6.25 mg film-coated tablets EFG
Carvedilol Sandoz 25 mg film-coated tablets EFG
carvedilol
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Note on the use in chronic heart failure:
Do not take Carvedilol Sandoz:
When carvedilol is administered at the same time as certain medications such as adrenaline (also epinephrine) for treating allergic reactions (anaphylactic) requires special caution.
You may respond less to these. Inform your doctor immediately if you have these diseases or circumstances that accompany them, as they should be taken into account before or during treatment.
Withdrawal symptoms (abstinence syndrome)
The treatment with carvedilol should not be interrupted suddenly. This is especially true in patients with heart disease due to the reduction of blood flow to the coronary arteries. Instead, the dose should be reduced gradually over a period of 2 weeks.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Carvedilol Sandoz.
Inform your doctor if you have any of the following diseases:
As with all medications with beta-blocking activity, you should not interrupt treatment with carvedilol abruptly. The dose should be reduced gradually according to your doctor's instructions.
Use in athletes
Inform athletes that this medication contains a component that may establish a positive analytical result in doping control.
Children and adolescents
Carvedilol is not recommended for use in children and adolescents under 18 years due to insufficient safety and efficacy data.
Advanced age
Older patients may be more sensitive to carvedilol and should be closely monitored.
Other medications and Carvedilol Sandoz
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication, including those acquired without a prescription.
This is extremely important, as taking more than one medication at a time may increase or decrease its effect.Therefore, do not take carvedilol with any other medication unless your doctor instructs you to.Note that these instructions may also apply to medications that have been used before or may be used afterwards.
Inform your doctor if you are taking any of the following medications:
Carvedilol Sandoz with food, drinks, and alcohol
Carvedilol should be avoided simultaneously or immediately after taking grapefruit or grapefruit juice. Grapefruit or grapefruit juice may cause an increase in carvedilol in the blood and cause unpredictable adverse effects. Excessive and simultaneous or occasional consumption of alcohol should also be avoided, as alcohol affects the effect of carvedilol.
Your doctor or pharmacist will inform you about the foods with which it is recommended to take carvedilol.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Carvedilol is not recommended for use during pregnancy and breastfeeding.
Carvedilol may cause fetal death in the uterus, as well as premature births. Additionally, adverse effects may occur in the fetus and newborn. After birth, the newborn has a higher risk of heart and lung problems.
Due to carvedilol excretion in breast milk, its administration during breastfeeding is not recommended.
Driving and operating machines
In some cases, carvedilol may impair the ability to drive or operate machines. This occurs especially when starting or changing treatment and when taken concurrently with alcohol.
Carvedilol Sandoz contains lactose
If your doctor has indicated that you have a intolerance to certain sugars, consult with him
before taking this medication.
The normal dose is:
Essential hypertension
Adults
Oral route. The recommended starting dose is 12.5 mg once a day for the first two days, followed by a recommended dose of 25 mg once a day. If necessary, your doctor may gradually increase the dose you receive (at intervals of at least two weeks) up to 50 mg once a day or in two doses of 25 mg each.
Advanced age
Oral route. The recommended starting dose for treatment is 12.5 mg once a day, which has provided satisfactory control in some patients. If the response is not adequate, your doctor will adjust the dose (at intervals of at least two weeks).
Ischemic cardiopathy
Adults
Oral route. The recommended starting dose for treatment is 12.5 mg twice a day (total 25 mg per day) for the first two days. Followed by a recommended dose of 25 mg twice a day (total 50 mg per day). If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks) up to 50 mg twice a day (total 100 mg/day).
Advanced age
Oral route. The maximum recommended dose for elderly patients is 50 mg administered in divided doses (twice a day).
Symptomatic congestive heart failure
Adults and advanced age
Your doctor will individually indicate the dose you should take, monitoring you during the adjustment to higher doses.
In case you are taking other medications for heart diseases (digitalis) or blood pressure control (diuretics and/or ACE inhibitors) and before starting treatment with carvedilol, your doctor will adjust the amount of these types of medications you should take.
In any case, the recommended starting dose for carvedilol treatment in symptomatic congestive heart failure is 3.12 mg twice a day (total 6.25 mg per day) for two weeks. If you tolerate this dose well, it can be increased later (at intervals of at least two weeks) up to 6.25 mg twice a day (total 12.5 mg per day).
Your doctor may prescribe you higher doses of carvedilol later (at least two weeks after).
If you weigh less than 85 kg, the maximum recommended dose is 25 mg twice a day (total 50 mg per day). If your weight is greater than 85 kg, the maximum recommended dose is 50 mg twice a day (100 mg per day).
Your doctor will indicate the duration of your treatment with carvedilol.
As a general rule, regardless of your disease, carvedilol withdrawal should be done gradually over a few days, or reduce the dose by half every three days.
Use in children and adolescents
Carvedilol is not recommended for use in children and adolescents under 18 years old as there are not enough data on safety and efficacy.
Guidelines for correct administration
The tablets should be taken with sufficient liquid, preferably with a glass of water.
If you have congestive heart failure (your heart has lost a little of its ability to pump blood and may cause difficulty breathing, weakness, and fluid accumulation), you should take carvedilol while eating, to avoid dizziness when getting up.
Remember to take your medication.
If you take more Carvedilol Sandoz than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Carvedilol Sandoz
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Carvedilol Sandoz
Carvedilol treatment should not be interrupted abruptly, especially if you have ischemic cardiopathy, a disease that causes the heart not to pump blood well. Your doctor will gradually reduce the dose over a few days until you stop taking carvedilol completely.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
The frequencies of side effects have been listed below according to the following definitions:
Very common (may affect more than 1 in 10 patients)
Common (may affect up to 1 in 10 patients)
Uncommon (may affect up to 1 in 100 patients)
Rare (may affect up to 1 in 1,000 patients)
Very rare (may affect up to 1 in 10,000 patients)
Frequency not known (cannot be estimated from available data)
The side effects that have been observed are as follows:
Infections and infestations
Common:Bronchitis, pneumonia, upper respiratory tract infections, urinary tract infections.
Nervous system disorders
Very common:Headache, dizziness, and weakness that are usually mild and occur mainly at the beginning of treatment.
Common:Presyncope, syncope (fainting), especially at the beginning of treatment.
Uncommon:Paresthesias (tingling sensation).
Mental and behavioural disorders
Common:Depressed mood, depression.
Uncommon:Sleep disorders.
Frequency not known:Hallucinations, nightmares, confusion, psychosis.
Cardiac disorders
Very common:Worsening of heart failure (the heart has lost some of its ability to pump blood).
Common:Bradycardia (decreased heart rate), fluid overload, increased blood volume in the body.
Uncommon:Atrioventricular (AV) block (heart problems), and angina pectoris (chest pain).
Frequency not known:Sinus arrest (a condition that makes heartbeats very slow or stop), especially in elderly patients or patients with other heart rhythm problems.
Vascular disorders
Very common:Low blood pressure.
Common:Postural hypotension (dizziness when standing up or changing body position), peripheral circulation disorders (cold hands and feet), worsening of symptoms in patients with intermittent claudication (increased pain in the legs when walking) or Raynaud's phenomenon (decreased blood flow to the fingers and toes, ears, and nose), hypertension.
Respiratory, thoracic and mediastinal disorders
Common:Asthma and breathing difficulties in predisposed patients, pulmonary congestion.
Rare:Nasal congestion.
Gastrointestinal disorders
Common:Gastrointestinal discomfort with symptoms such as nausea, diarrhea, abdominal pain, indigestion, vomiting.
Uncommon:Constipation.
Rare:Dry mouth.
Skin and subcutaneous tissue disorders
Uncommon:Cutaneous reactions (e.g., allergic exanthema, dermatitis, urticaria, pruritus, psoriasis, lichen planus-like skin lesions).
Frequency not known:Hair loss, severe cutaneous adverse reactions (e.g., toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome), excessive sweating (hyperhidrosis).
Haematological and lymphatic system disorders
Common:Decreased red blood cell count in blood (anemia).
Rare:Decreased platelet count in blood (thrombocytopenia)
Very rare:Decreased white blood cell count in blood (leucopenia).
Hepatobiliary disorders
Very rare:Alterations in serum transaminases (changes in the amount of certain liver enzymes in the blood).
Ocular disorders
Common:Decreased tear production (dry eye), eye irritation, visual disturbances.
Renal and urinary disorders
Common:Acute kidney failure (kidney not functioning properly) and kidney function disorders in patients with diffuse vascular disease and/or altered kidney function.
Rare:Urination problems.
Frequency not known:Urinary incontinence in women (disappears when stopping medication).
Immune system disorders
Very rare:Allergic reactions.
Musculoskeletal and connective tissue disorders
Common:Arm or leg pain.
Reproductive and breast disorders
Uncommon:Impotence.
Metabolism and nutrition disorders
Common:Worsening of blood sugar control in patients with diabetes (hyperglycaemia, hypoglycaemia), weight gain, increased blood cholesterol.
Frequency not known:It is possible that latent diabetes mellitus may be manifested, or that existing diabetes may worsen.
General disorders and administration site conditions
Very common:Fatigue.
Common:Pain, edema (fluid retention, swelling of legs, ankles, and feet).
If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 30°C.
Store in the original packaging to protect it from light.
Do not use this medication after the expiration date that appears on the packaging after CAD/EXP. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and unused medications at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Carvedilol Sandoz 6.25 mg:
Composition of Carvedilol Sandoz 25 mg:
Appearance of the product and content of the packaging
Carvedilol Sandoz 6.25 mg are round, convex tablets, yellow in color, scored on both faces, and with the mark C2 on one face.
They are presented in packs of 28 tablets.
Carvedilol Sandoz 25 mg are round, convex tablets, white in color, scored on both faces, and with the mark C4 on one face.
They are presented in packs of 28 tablets.
Holder of the marketing authorization and responsible manufacturer
Holder of the marketing authorization:
Sandoz Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid
Spain
Responsible manufacturer:
Salutas Pharma GmbH
Otto Von Guericke Allee 1
39179 Barleben
Germany
Last review date of this leaflet:January 2025
The detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
O preço médio do Carvedilol sandoz 6,25 mg comprimidos efg em julho de 2025 é de cerca de 2.5 EUR. Os valores podem variar consoante a região, a farmácia e a necessidade de receita. Confirme sempre com uma farmácia local ou fonte online para obter informações atualizadas.
Tem perguntas sobre este medicamento ou sintomas? Obtenha orientação de um médico qualificado, de forma prática e segura.